Merck’s Once-Weekly Diabetes Pill Is as Good as Januvia in Study

  • Drugmaker plans to file drug with the FDA by the end of year
  • Pill could help Merck in highly competitive diabetes market

Merck & Co.’s experimental, once-a-week diabetes drug was as effective at regulating blood sugar as its top-selling daily pill Januvia, according to a study the company will submit to U.S. regulators this year as part of its effort to get the treatment approved.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.